A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome

Claudio Ponticelli, Gianfranco Rizzoni, Alberto Edefonti, Paolo Altieri, Emilio Rivolta, Stefano Rinaldi, Luciana Ghio, Egidio Lusvarghi, Rosanna Gusmano, Francesco Locatelli, Sonia Pasquali, Alfonso Castellani, Ornella Della Casa-Alberighi

Research output: Contribution to journalArticle

255 Citations (Scopus)

Abstract

To compare the efficacy (induction of remission) and safety of cyclosporine (CsA) with those of supportive therapy in patients with steroid-resistant idiopathic nephrotic syndrome (INS), we organized an open, prospective, randomized, multicentric, controlled study for parallel groups, stratified for adults and children. Forty-five patients with steroid-resistant INS were randomly assigned to supportive therapy or CsA (5 mg/kg/day for adults, 6 mg/kg/day for children) for six months, then tapered off by 25% every two months until complete discontinuation. Four patients were lost to follow-up. During the first year 13/22 CsA-treated patients versus three of 19 controls attained remission of the nephrotic syndrome (P <0.001). A symptom score was assessed at time O and at six months. The mean score significantly decreased in the CsA group (P <0.001), but remained unchanged in the controls. At month 6 the mean urinary protein excretion, the mean serum proteins and plasma cholesterol had significantly improved in the CsA group but were not changed in the controls. There were no significant differences in serum creatinine and creatinine clearance between treatments (interaction time* treatments, P = 0.089 and P = 0.935, respectively) at month 6 versus basal. The CsA-related side-effects were mild; no significant difference in blood pressure between the two groups was seen at any time. This study shows that CsA can bring about remission in some 60% of patients with steroid-resistant INS. In patients with normal renal function and without severe hypertension, CsA at the therapeutic scheme adopted did not produce severe renal or extrarenal toxicity.

Original languageEnglish
Pages (from-to)1377-1384
Number of pages8
JournalKidney International
Volume43
Issue number6
Publication statusPublished - Jun 1993

Fingerprint

Cyclosporine
Creatinine
Kidney
Therapeutics
Remission Induction
Lost to Follow-Up
Nephrotic Syndrome
Nephrotic syndrome, idiopathic, steroid-resistant
Blood Proteins
Cholesterol
Blood Pressure
Hypertension
Safety
Serum
Proteins

ASJC Scopus subject areas

  • Nephrology

Cite this

Ponticelli, C., Rizzoni, G., Edefonti, A., Altieri, P., Rivolta, E., Rinaldi, S., ... Della Casa-Alberighi, O. (1993). A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney International, 43(6), 1377-1384.

A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. / Ponticelli, Claudio; Rizzoni, Gianfranco; Edefonti, Alberto; Altieri, Paolo; Rivolta, Emilio; Rinaldi, Stefano; Ghio, Luciana; Lusvarghi, Egidio; Gusmano, Rosanna; Locatelli, Francesco; Pasquali, Sonia; Castellani, Alfonso; Della Casa-Alberighi, Ornella.

In: Kidney International, Vol. 43, No. 6, 06.1993, p. 1377-1384.

Research output: Contribution to journalArticle

Ponticelli, C, Rizzoni, G, Edefonti, A, Altieri, P, Rivolta, E, Rinaldi, S, Ghio, L, Lusvarghi, E, Gusmano, R, Locatelli, F, Pasquali, S, Castellani, A & Della Casa-Alberighi, O 1993, 'A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome', Kidney International, vol. 43, no. 6, pp. 1377-1384.
Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney International. 1993 Jun;43(6):1377-1384.
Ponticelli, Claudio ; Rizzoni, Gianfranco ; Edefonti, Alberto ; Altieri, Paolo ; Rivolta, Emilio ; Rinaldi, Stefano ; Ghio, Luciana ; Lusvarghi, Egidio ; Gusmano, Rosanna ; Locatelli, Francesco ; Pasquali, Sonia ; Castellani, Alfonso ; Della Casa-Alberighi, Ornella. / A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. In: Kidney International. 1993 ; Vol. 43, No. 6. pp. 1377-1384.
@article{0d641523403d4323867567caa5b7caaf,
title = "A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome",
abstract = "To compare the efficacy (induction of remission) and safety of cyclosporine (CsA) with those of supportive therapy in patients with steroid-resistant idiopathic nephrotic syndrome (INS), we organized an open, prospective, randomized, multicentric, controlled study for parallel groups, stratified for adults and children. Forty-five patients with steroid-resistant INS were randomly assigned to supportive therapy or CsA (5 mg/kg/day for adults, 6 mg/kg/day for children) for six months, then tapered off by 25{\%} every two months until complete discontinuation. Four patients were lost to follow-up. During the first year 13/22 CsA-treated patients versus three of 19 controls attained remission of the nephrotic syndrome (P <0.001). A symptom score was assessed at time O and at six months. The mean score significantly decreased in the CsA group (P <0.001), but remained unchanged in the controls. At month 6 the mean urinary protein excretion, the mean serum proteins and plasma cholesterol had significantly improved in the CsA group but were not changed in the controls. There were no significant differences in serum creatinine and creatinine clearance between treatments (interaction time* treatments, P = 0.089 and P = 0.935, respectively) at month 6 versus basal. The CsA-related side-effects were mild; no significant difference in blood pressure between the two groups was seen at any time. This study shows that CsA can bring about remission in some 60{\%} of patients with steroid-resistant INS. In patients with normal renal function and without severe hypertension, CsA at the therapeutic scheme adopted did not produce severe renal or extrarenal toxicity.",
author = "Claudio Ponticelli and Gianfranco Rizzoni and Alberto Edefonti and Paolo Altieri and Emilio Rivolta and Stefano Rinaldi and Luciana Ghio and Egidio Lusvarghi and Rosanna Gusmano and Francesco Locatelli and Sonia Pasquali and Alfonso Castellani and {Della Casa-Alberighi}, Ornella",
year = "1993",
month = "6",
language = "English",
volume = "43",
pages = "1377--1384",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome

AU - Ponticelli, Claudio

AU - Rizzoni, Gianfranco

AU - Edefonti, Alberto

AU - Altieri, Paolo

AU - Rivolta, Emilio

AU - Rinaldi, Stefano

AU - Ghio, Luciana

AU - Lusvarghi, Egidio

AU - Gusmano, Rosanna

AU - Locatelli, Francesco

AU - Pasquali, Sonia

AU - Castellani, Alfonso

AU - Della Casa-Alberighi, Ornella

PY - 1993/6

Y1 - 1993/6

N2 - To compare the efficacy (induction of remission) and safety of cyclosporine (CsA) with those of supportive therapy in patients with steroid-resistant idiopathic nephrotic syndrome (INS), we organized an open, prospective, randomized, multicentric, controlled study for parallel groups, stratified for adults and children. Forty-five patients with steroid-resistant INS were randomly assigned to supportive therapy or CsA (5 mg/kg/day for adults, 6 mg/kg/day for children) for six months, then tapered off by 25% every two months until complete discontinuation. Four patients were lost to follow-up. During the first year 13/22 CsA-treated patients versus three of 19 controls attained remission of the nephrotic syndrome (P <0.001). A symptom score was assessed at time O and at six months. The mean score significantly decreased in the CsA group (P <0.001), but remained unchanged in the controls. At month 6 the mean urinary protein excretion, the mean serum proteins and plasma cholesterol had significantly improved in the CsA group but were not changed in the controls. There were no significant differences in serum creatinine and creatinine clearance between treatments (interaction time* treatments, P = 0.089 and P = 0.935, respectively) at month 6 versus basal. The CsA-related side-effects were mild; no significant difference in blood pressure between the two groups was seen at any time. This study shows that CsA can bring about remission in some 60% of patients with steroid-resistant INS. In patients with normal renal function and without severe hypertension, CsA at the therapeutic scheme adopted did not produce severe renal or extrarenal toxicity.

AB - To compare the efficacy (induction of remission) and safety of cyclosporine (CsA) with those of supportive therapy in patients with steroid-resistant idiopathic nephrotic syndrome (INS), we organized an open, prospective, randomized, multicentric, controlled study for parallel groups, stratified for adults and children. Forty-five patients with steroid-resistant INS were randomly assigned to supportive therapy or CsA (5 mg/kg/day for adults, 6 mg/kg/day for children) for six months, then tapered off by 25% every two months until complete discontinuation. Four patients were lost to follow-up. During the first year 13/22 CsA-treated patients versus three of 19 controls attained remission of the nephrotic syndrome (P <0.001). A symptom score was assessed at time O and at six months. The mean score significantly decreased in the CsA group (P <0.001), but remained unchanged in the controls. At month 6 the mean urinary protein excretion, the mean serum proteins and plasma cholesterol had significantly improved in the CsA group but were not changed in the controls. There were no significant differences in serum creatinine and creatinine clearance between treatments (interaction time* treatments, P = 0.089 and P = 0.935, respectively) at month 6 versus basal. The CsA-related side-effects were mild; no significant difference in blood pressure between the two groups was seen at any time. This study shows that CsA can bring about remission in some 60% of patients with steroid-resistant INS. In patients with normal renal function and without severe hypertension, CsA at the therapeutic scheme adopted did not produce severe renal or extrarenal toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0027162801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027162801&partnerID=8YFLogxK

M3 - Article

C2 - 8315953

AN - SCOPUS:0027162801

VL - 43

SP - 1377

EP - 1384

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -